MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that its Chief Executive Officer, Maria Maccecchini, Ph.D., will present at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The presentation is scheduled from 12:40 to 1:10 p.m. ET and will be accessible via the event’s virtual platform.
Dr. Maccecchini’s presentation will focus on the company’s latest achievements, including the progress of its pivotal Phase 3 clinical trial for buntanetap, a promising treatment for early Alzheimer’s disease (AD). She will also discuss the company’s strategic initiatives to advance a New Drug Application (NDA) for buntanetap, which is being developed for both symptomatic relief and potential disease-modifying effects.
The Oppenheimer Healthcare Life Sciences Conference is a high-profile event that connects leaders from the healthcare and life sciences industries with prominent investors. It provides a platform for companies to showcase their innovations, gain exposure, and explore investment opportunities.
Annovis Bio’s participation highlights the company’s dedication to developing breakthrough treatments for neurodegenerative diseases. The advancements discussed during the conference could strengthen its market presence and potentially reshape therapeutic options in the healthcare sector.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.